Nateglinide is a novel D-
phenylalanine derivative that inhibits
ATP-sensitive K+ channels in pancreatic beta-cells in the presence of
glucose and thereby stimulates the prandial release of
insulin.
Nateglinide reduces fasting and mealtime
blood glucose levels in animals, healthy volunteers, and patients with type 2 (
non-insulin-dependent) diabetes mellitus, and produces prompt prandial
insulin responses with return to baseline
insulin levels between meals. In randomised, double-blind 24-week studies in patients with
type 2 diabetes, oral
nateglinide 120 mg 3 times daily before meals improved glycaemic control significantly relative to placebo.
Nateglinide 120 mg plus
metformin 500 mg, both 3 times daily, conferred greater glycaemic improvement than either
drug given alone, and
nateglinide 60 or 120 mg 3 times daily plus
metformin 1 g twice daily was superior to
metformin plus placebo.
Nateglinide 120 mg 3 times daily significantly reduced hyperglycaemia relative to placebo in a 16-week double-blind study in patients with
type 2 diabetes mellitus. Combination
therapy with
troglitazone 600 mg daily produced significantly better glycaemic control than either
drug given as monotherapy. Mild hypoglycaemia was the most frequently reported adverse event (1.3% of patients)
after treatment with
nateglinide 120 mg 3 times daily in a 16-week clinical study. No clinically significant abnormalities in laboratory results, ECGs, vital signs or physical examination findings have been noted in patients taking the
drug.